{"id":34417,"date":"2025-05-29T15:59:52","date_gmt":"2025-05-29T07:59:52","guid":{"rendered":"https:\/\/flcube.com\/?p=34417"},"modified":"2025-05-29T15:59:53","modified_gmt":"2025-05-29T07:59:53","slug":"lupeng-pharmas-rocbrutinib-near-approval-for-mantle-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34417","title":{"rendered":"Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma"},"content":{"rendered":"\n

Guangzhou Lupeng Pharmaceutical Co., Ltd’s rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton’s tyrosine kinase (BTK) inhibitors.<\/p>\n\n\n\n

Rocbrutinib Innovation<\/strong>
Rocbrutinib stands out as the world’s first fourth-generation dual covalent\/non-covalent BTK inhibitor. It effectively targets multiple BTK mutations that confer resistance to first, second, and third-generation inhibitors. The drug has demonstrated significant efficacy in clinical studies, particularly in relapsed\/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma (R\/R non-GCB DLBCL).<\/p>\n\n\n\n

Regulatory Milestones and Clinical Trial Progress<\/strong>
Rocbrutinib was awarded Breakthrough Therapy Designation (BTD) in China in May 2024, marking it as the first drug of its kind to achieve this status for DLBCL in the country and globally for BTK inhibitors. Recently, the drug also received clearance for a pivotal Phase II regulatory study targeting R\/R non-GCB DLBCL in China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Guangzhou Lupeng Pharmaceutical Co., Ltd’s rocbrutinib is currently under New Drug Application (NDA) review at…<\/p>\n","protected":false},"author":1,"featured_media":34418,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,3432,38,33],"class_list":["post-34417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-lupeng-pharmaceutical","tag-market-approval-filings","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nLupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangzhou Lupeng Pharmaceutical Co., Ltd's rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton's tyrosine kinase (BTK) inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34417\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Guangzhou Lupeng Pharmaceutical Co., Ltd's rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton's tyrosine kinase (BTK) inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34417\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T07:59:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T07:59:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma\",\"datePublished\":\"2025-05-29T07:59:52+00:00\",\"dateModified\":\"2025-05-29T07:59:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417\"},\"wordCount\":193,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2906.webp\",\"keywords\":[\"Cancer\",\"Lupeng Pharmaceutical\",\"Market approval filings\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34417#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34417\",\"name\":\"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2906.webp\",\"datePublished\":\"2025-05-29T07:59:52+00:00\",\"dateModified\":\"2025-05-29T07:59:53+00:00\",\"description\":\"Guangzhou Lupeng Pharmaceutical Co., Ltd's rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton's tyrosine kinase (BTK) inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34417\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2906.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34417#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry","description":"Guangzhou Lupeng Pharmaceutical Co., Ltd's rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton's tyrosine kinase (BTK) inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34417","og_locale":"en_US","og_type":"article","og_title":"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma","og_description":"Guangzhou Lupeng Pharmaceutical Co., Ltd's rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton's tyrosine kinase (BTK) inhibitors.","og_url":"https:\/\/flcube.com\/?p=34417","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-29T07:59:52+00:00","article_modified_time":"2025-05-29T07:59:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34417#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34417"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma","datePublished":"2025-05-29T07:59:52+00:00","dateModified":"2025-05-29T07:59:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34417"},"wordCount":193,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp","keywords":["Cancer","Lupeng Pharmaceutical","Market approval filings","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34417#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34417","url":"https:\/\/flcube.com\/?p=34417","name":"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34417#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp","datePublished":"2025-05-29T07:59:52+00:00","dateModified":"2025-05-29T07:59:53+00:00","description":"Guangzhou Lupeng Pharmaceutical Co., Ltd's rocbrutinib is currently under New Drug Application (NDA) review at the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) and has been granted priority review status. The company is seeking approval for its use in adult mantle cell lymphoma (MCL) patients who have previously been treated with Bruton's tyrosine kinase (BTK) inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34417#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34417"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34417#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp","width":1080,"height":608,"caption":"Lupeng Pharma's Rocbrutinib Near Approval for Mantle Cell Lymphoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34417#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34417"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34417\/revisions"}],"predecessor-version":[{"id":34419,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34417\/revisions\/34419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34418"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}